News

Treating the Seeds of Cancer

athernal bio is developing the first immunotherapies for high-risk clonal haematopoiesis — addressing blood cancer precursor condition with the aim of stopping cancer before it starts through early and proactive therapeutic intervention.

Explore

MISSION

To design, develop and deliver the first targeted immunotherapies for high-risk blood cancer precursor conditions

UNMET NEED

Clonal haematopoiesis: a silent but widespread risk

Clonal haematopoiesis (CH) occurs when blood stem cells acquire mutations that give them a growth advantage. These altered stem cells expand over time, increasing the risk of blood cancers such as acute myeloid leukemia (AML) and contributing to cardiovascular and other age-related diseases. Despite its prevalence and impact, there are currently no approved therapies for CH.

Patient receiving chemotherapy treatment

15%

of people over 60

live with clonal haematopoesis

25%

Cancer survivors

treated with chemotherapy or radiotherapy develop clonal haematopoesis

Clonal Hematopoiesis

Cancer Pre-cursor Disease

10x

Blood Cancer Risk

15%

of people over 60

live with clonal haematopoesis

25%

Cancer survivors

treated with chemotherapy or radiotherapy develop clonal haematopoesis

Clonal Hematopoiesis

Cancer Pre-cursor Disease

10x

Blood Cancer Risk

15%

of people over 60

live with clonal haematopoesis

25%

Cancer survivors

treated with chemotherapy or radiotherapy develop clonal haematopoesis

Clonal Hematopoiesis

Cancer Pre-cursor Disease

10x

Blood Cancer Risk

OUR APPROACH

A new therapeutic category for oncology

We are building immunotherapies that train the immune system to detect and eliminate CH-affected stem cells, addressing the earliest step in the development of blood cancers.

Frontline immunotherapy

Taking immunotherapy to the earliest stage of disease, before blood cancers emerge.

Precision by Design

Targeted to maximise effectiveness while minimising risk.

A LNP therapy with a vial in the background

Accelerated clinical strategy

Initially focusing on orphan indications with clear regulatory pathways to bring therapies to patients faster.

Transformative opportunity

Delivering the first treatment option for a condition affecting millions and linked to multiple diseases.

PIPELINE

Lead Clinical Programs

athernal bio is developing targeted immunotherapies to treat clonal haematopoiesis before cancers become established.

Program

Discovery

Preclinical

Pre-IND

Phase I

ath-00l

Rare blood disorders with accelerated CH and AML risk

ath-00l

Rare blood disorders with accelerated CH and AML risk

ath-00l

Rare blood disorders with accelerated CH and AML risk

ath-002

Cytotoxic injury

Post-chemo & RT* in cancer survivors

ath-002

Cytotoxic injury

Post-chemo & RT* in cancer survivors

ath-002

Cytotoxic injury

Post-chemo & RT* in cancer survivors

ath-003

Age-related CH in adults over 65

ath-003

Age-related CH in adults over 65

ath-003

Age-related CH in adults over 65

SCIENCE

Targeting the First Step in Cancer Evolution

Clonal haematopoiesis (CH) arises when blood stem cells, also called haematopoietic stem cells (HSCs), acquire mutations that give them a survival and growth advantage. Over time, these altered stem cells expand, reshaping the blood system and significantly increasing the risk of blood cancers and other diseases.

Infographic showing the four stages of clonal hematopoiesis

Healthy HSCs

Normally, haematopoietic stem cells produce a balanced mix of healthy blood cells.

Mutated HSCs

Some acquire mutations that give them an advantage.

Clonal Expansion

These altered stem cells grow faster and outcompete normal cells.

Disease Risk

As the altered stem cells expand, they drive inflammation and raise the risk of:

SCIENCE

Targeting the First Step in Cancer Evolution

Healthy HSCs

Normally, haematopoietic stem cells produce a balanced mix of healthy blood cells.

Mutated HSCs

Some acquire mutations that give them an advantage.

Clonal Expansion

These altered stem cells grow faster and outcompete normal cells.

Disease Risk

As the altered stem cells expand, they drive inflammation and raise the risk of:

SCIENCE

Targeting the First Step in Cancer Evolution

Healthy HSCs

Normally, haematopoietic stem cells produce a balanced mix of healthy blood cells.

Mutated HSCs

Some acquire mutations that give them an advantage.

Clonal Expansion

These altered stem cells grow faster and outcompete normal cells.

Disease Risk

As the altered stem cells expand, they drive inflammation and raise the risk of:

EXPERTS

Meet our team

A diverse group of passionate professionals, each bringing unique skills and experiences to drive innovation and excellence in every project we undertake.